• Je něco špatně v tomto záznamu ?

A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding

MK. Madsen, PM. Fisher, DS. Stenbæk, S. Kristiansen, D. Burmester, S. Lehel, T. Páleníček, M. Kuchař, C. Svarer, B. Ozenne, GM. Knudsen

. 2020 ; 33 (-) : 71-80. [pub] 20200304

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026733

A single dose of the serotonin 2A receptor (5-HT2AR) agonist psilocybin can have long-lasting beneficial effects on mood, personality, and potentially on mindfulness, but underlying mechanisms are unknown. Here, we for the first time conduct a study that assesses psilocybin effects on cerebral 5-HT2AR binding with [11C]Cimbi-36 positron emission tomography (PET) imaging and on personality and mindfulness. Ten healthy and psychedelic-naïve volunteers underwent PET neuroimaging of 5-HT2AR at baseline (BL) and one week (1W) after a single oral dose of psilocybin (0.2-0.3 mg/kg). Personality (NEO PI-R) and mindfulness (MAAS) questionnaires were completed at BL and at three-months follow-up (3M). Paired t-tests revealed statistically significant increases in personality Openness (puncorrected = 0.04, mean change [95%CI]: 4.2[0.4;∞]), which was hypothesized a priori to increase, and mindfulness (pFWER = 0.02, mean change [95%CI]: 0.5 [0.2;0.7]). Although 5-HT2AR binding at 1W versus BL was similar across individuals (puncorrected = 0.8, mean change [95%CI]: 0.007 [-0.04;0.06]), a post hoc linear regression analysis showed that change in mindfulness and 5-HT2AR correlated negatively (β [95%CI] = -5.0 [-9.0; -0.9], pFWER= 0.046). In conclusion, we confirm that psilocybin intake is associated with long-term increases in Openness and - as a novel finding - mindfulness, which may be a key element of psilocybin therapy. Cerebral 5-HT2AR binding did not change across individuals but the negative association between changes in 5-HT2AR binding and mindfulness suggests that individual change in 5-HT2AR levels after psilocybin is variable and represents a potential mechanism influencing long-term effects of psilocybin on mindfulness.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026733
003      
CZ-PrNML
005      
20211026132648.0
007      
ta
008      
211013s2020 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euroneuro.2020.02.001 $2 doi
035    __
$a (PubMed)32146028
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Madsen, Martin Korsbak $u Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark
245    12
$a A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding / $c MK. Madsen, PM. Fisher, DS. Stenbæk, S. Kristiansen, D. Burmester, S. Lehel, T. Páleníček, M. Kuchař, C. Svarer, B. Ozenne, GM. Knudsen
520    9_
$a A single dose of the serotonin 2A receptor (5-HT2AR) agonist psilocybin can have long-lasting beneficial effects on mood, personality, and potentially on mindfulness, but underlying mechanisms are unknown. Here, we for the first time conduct a study that assesses psilocybin effects on cerebral 5-HT2AR binding with [11C]Cimbi-36 positron emission tomography (PET) imaging and on personality and mindfulness. Ten healthy and psychedelic-naïve volunteers underwent PET neuroimaging of 5-HT2AR at baseline (BL) and one week (1W) after a single oral dose of psilocybin (0.2-0.3 mg/kg). Personality (NEO PI-R) and mindfulness (MAAS) questionnaires were completed at BL and at three-months follow-up (3M). Paired t-tests revealed statistically significant increases in personality Openness (puncorrected = 0.04, mean change [95%CI]: 4.2[0.4;∞]), which was hypothesized a priori to increase, and mindfulness (pFWER = 0.02, mean change [95%CI]: 0.5 [0.2;0.7]). Although 5-HT2AR binding at 1W versus BL was similar across individuals (puncorrected = 0.8, mean change [95%CI]: 0.007 [-0.04;0.06]), a post hoc linear regression analysis showed that change in mindfulness and 5-HT2AR correlated negatively (β [95%CI] = -5.0 [-9.0; -0.9], pFWER= 0.046). In conclusion, we confirm that psilocybin intake is associated with long-term increases in Openness and - as a novel finding - mindfulness, which may be a key element of psilocybin therapy. Cerebral 5-HT2AR binding did not change across individuals but the negative association between changes in 5-HT2AR binding and mindfulness suggests that individual change in 5-HT2AR levels after psilocybin is variable and represents a potential mechanism influencing long-term effects of psilocybin on mindfulness.
650    _2
$a dospělí $7 D000328
650    _2
$a benzylaminy $7 D001596
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a halucinogeny $x aplikace a dávkování $x farmakologie $7 D006213
650    _2
$a lidé $7 D006801
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    12
$a všímavost $7 D064866
650    _2
$a neokortex $x diagnostické zobrazování $x účinky léků $x metabolismus $7 D019579
650    _2
$a neuropsychologické testy $7 D009483
650    _2
$a osobnost $x účinky léků $7 D010551
650    _2
$a osobnostní testy $7 D010556
650    _2
$a fenethylaminy $7 D010627
650    _2
$a pozitronová emisní tomografie $7 D049268
650    _2
$a psilocybin $x aplikace a dávkování $x farmakologie $7 D011562
650    _2
$a receptor serotoninový 5-HT2A $x účinky léků $x metabolismus $7 D044402
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Fisher, Patrick MacDonald $u Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark
700    1_
$a Stenbæk, Dea Siggaard $u Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark
700    1_
$a Kristiansen, Sara $u Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark
700    1_
$a Burmester, Daniel $u Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark
700    1_
$a Lehel, Szabolcs $u PET and Cyclotron Unit, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark
700    1_
$a Páleníček, Tomas $u National Institute of Mental Health, 250 67 Klecany, Czech Republic
700    1_
$a Kuchař, Martin $u National Institute of Mental Health, 250 67 Klecany, Czech Republic; Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology, 166 28 Prague, Czech Republic
700    1_
$a Svarer, Claus $u Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark
700    1_
$a Ozenne, Brice $u Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark; Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Knudsen, Gitte M $u Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark. Electronic address: gmk@nru.dk
773    0_
$w MED00001656 $t European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology $x 1873-7862 $g Roč. 33, č. - (2020), s. 71-80
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32146028 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132654 $b ABA008
999    __
$a ok $b bmc $g 1715469 $s 1147240
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 33 $c - $d 71-80 $e 20200304 $i 1873-7862 $m European neuropsychopharmacology $n Eur Neuropsychopharmacol $x MED00001656
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace